KLRA
KLRA clinical trials: Kailera Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Kailera Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 9
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
KLRA on the catalyst calendar · KLRA registry changes
- Primary completion Mar 27, 2028Sponsor estimatePhase 3NCT07284901Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesKailera · Obesity With DiabetesActive, not recruitingKLRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1NCT07924761A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants...Kailera · Overweight or ObesityNot yet recruitingKLRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 3NCT07284979Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who...Kailera · ObesityActive, not recruitingKLRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 3NCT07284875Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have...Kailera · ObesityActive, not recruitingKLRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 8, 2028Sponsor estimatePhase 1NCT07793929A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of RibupatideKailera · End Stage Renal DiseaseRecruitingKLRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2027Sponsor estimatePhase 2NCT07497880Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityKailera · ObesityActive, not recruitingKLRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 2NCT07458269Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesKailera · ObesityActive, not recruitingKLRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2026ActualPhase 1NCT07294898A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or OverweightKailera · ObesityCompletedKLRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 13, 2025ActualPhase 1NCT07044401A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass IndicesKailera · Healthy VolunteersCompletedKLRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner